IM83 CAR-T cells
Phase 1Cell therapy
IM83 CAR-T cells is one of 46 biologic programs targeting Osteosarcoma. It is currently in Phase 1.
1
Indications
2
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Osteosarcoma
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Trexall
Jazz PharmaceuticalsPhase 3
Verzenio
Eli LillyApproved
Adriamycin
PfizerPhase 3
Lithobid
SSolvay Pharmaceuticals
Approved
Ifex
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Paraplatin
AAvyxa
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Vepesid
AAvyxa
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Osteosarcoma1 trial
IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma
Not yet recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT06412458·9 enrolled
Safety and Efficacy1 trial
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT05123209·12 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM83 CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details